Advertisement

Acta Neurologica Belgica

, Volume 118, Issue 3, pp 361–377 | Cite as

Infectious agents and different course of multiple sclerosis: a systematic review

  • Alia Saberi
  • Shahin Akhondzadeh
  • Samaneh Kazemi
Review
  • 128 Downloads

Abstract

Multiple sclerosis (MS) causes demyelination of white matter of central nervous system and neuro-degeneration due to inflammation. Different types of MS, as well as disease progression, come with different pathology and pathophysiology. The objective of this study was to evaluate the possible association between different micro-organisms and the relapse or progression of MS. Studies indexed in Medline/PMC, Scopus and Web of Science published without time and language limitation until March 2017 were identified through the search terms “infection” or “infectious” and “multiple sclerosis”. A total of 20878 abstracts were identified through the initial search terms. Selection of articles and assessment of their quality was done based on Cochrane library guidelines. Full texts were reviewed for 33 articles out of which 14 articles met the criteria for inclusion. Different micro-organisms are known to play roles in the pathogenesis of MS and its relapse; including Human herpesvirus 6 (HHV-6), Human herpesvirus 7 (HHV-7), Epstein–Barr virus (EBV), Chlamydia pneumoniae and Torque teno virus (TTV). But in this review only HHV-6, C. pneumoniae and TTV have been considered to play a role in disease progression in some studies and not all of them. This review concluded that some micro-organisms such as HHV-6, C. pneumoniae and TTV have been considered as cofactors to make MS a progressive type. It should be considered that these findings do not necessarily rule out the role of other pathogens in MS progression but may represent population differences or different sensitivity of the technique used.

Keywords

Infection Multiple sclerosis Relapsing–remitting Progressive 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

The authors confirm independence from the sponsors; the content of the article has not been influenced by the sponsors.

References

  1. 1.
    Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH (1992) Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neural 31:333–336Google Scholar
  2. 2.
    Lassmann H, Raine CS, Antel J, Prineas JW (1998) Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 86:213–217PubMedGoogle Scholar
  3. 3.
    Gilden DH, Devlin ME, Burgoon MP, Owens GP (1996) The search for virus in multiple sclerosis brain. Mult Scler 2:179–183PubMedGoogle Scholar
  4. 4.
    Farid R, Norasteh A, Hatamian H (2016) The effect of core stability exercise program on the balance of patients with multiple sclerosis. Caspian J Neurol Sci 2(4):9–17Google Scholar
  5. 5.
    Semnani M, Mashayekhi F, Azarnia M, Salehi Z (2016) Effects of green tea epigallocatechin-3-gallate (EGCG) on proteolipid protein (PLP) and oligodendrocyte transcription factor 1 (Olig1) expression in the cerebral cortex of cuprizone induced multiple sclerosis mice; a western blot study. Caspian J Neurol Sci 2(6):1–9Google Scholar
  6. 6.
    Saeidi M, Raftari S, Roudbary S, Rezaeitalab F, Hatamian H (2016) Peripheral neuro electrodiagnostic abnormalities in patients with multiple sclerosis: a cross sectional study. Caspian J Neurol Sci 2(7):41–48Google Scholar
  7. 7.
    Janalipour K, Kafi M, Hatamian H, Rezapour P (2017) The effectiveness of yoga therapy in reducing anxiety, stress and depression in women with multiple sclerosis. Caspian J Neurol Sci 3(10):151–158Google Scholar
  8. 8.
    Amir F, Ahadi H, Nikkhah K, Seirafi M (2017) The effectiveness of acceptance and commitment group therapy and group logotherapy in reducing perceived stress among MS patients. Caspian J Neurol Sci 3(11):175–184Google Scholar
  9. 9.
    Saberi A, Hatamian HR, Nemati SH, Banan R (2012) Hearing statement in multiple sclerosis: a case control study using auditory brainstem responses and otoacoustic emissions. Acta Med Iran 50(10):679–683PubMedGoogle Scholar
  10. 10.
    Saberi A, Roudbary SA, Hatamian HR, Akbari MS, Sedigh-Rahim-Abadi MR (2012) The type of multiple sclerosis when accompanied with seizure: can seizure predict the progression of MS? Akt Neurol 39:1–5. (text in German) Google Scholar
  11. 11.
    Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343:938–952PubMedGoogle Scholar
  12. 12.
    Lublin DF, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46:907–11Google Scholar
  13. 13.
    Etemadifar M, Moeini P, Nabavi S (2017) Fingolimod versus high dose interferon beta-1a in multiple sclerosis: a randomized clinical trial. Caspian J Neurol Sci 3(8):1–8Google Scholar
  14. 14.
    Roudbary S, Yousefzadeh-Chabok S, Behzadnia H, Bakhshayesh-Eghbali B, Emamhadi M, Ghayeghran A et al (2017) Non-adherence to disease-modifying treatments in patients with multiple sclerosis. Caspian J Neurol Sci 3(10):128–134Google Scholar
  15. 15.
    McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913–919PubMedGoogle Scholar
  16. 16.
    Etemadifar M, Ghadimi M, Ghadimi K, Alsahebfosoul F (2017) The serum amyloid β level in multiple sclerosis: a case–control study. Caspian J Neurol Sci 3(11):214–221Google Scholar
  17. 17.
    Walvoort MTC, Testa C, Eilam R et al (2016) Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of nontypeable Haemophilus influenzae. Sci Rep 6:39430.  https://doi.org/10.1038/srep39430 PubMedGoogle Scholar
  18. 18.
    Ashtari F, Saberi A, Shayegannejad V, Khosravi AR, Sherkat R, Khosravi E (2007) Association between Chlamydia pneumoniae infection and carotid atherosclerotic plaques. JRMS 12(4):165–171Google Scholar
  19. 19.
    Ashtari F, Shayghannejad V, Saberi A, Karkheyran F, Khosravi E (2007) Chlamydia pneumonia infection and thrombotic ischemic stroke. J Isfahan Med School 24(83):8–14 [Text in Persian].Google Scholar
  20. 20.
    Ashtari F, Shayegannejad V, Khosravi AR, Alia Saberi A, Niknazar MA (2006) The influence of Chlamydia pneumoniae infection on Intima-Media-thickness (IMT) in common carotid artery. ARYA Atheroscler 2(3):130–133Google Scholar
  21. 21.
    Ashtari F, Shayghannejad V, Saberi A, Rabiei E (2006) Association between Helicobacter pylori infection and carotid atherosclerotic plaque. Iran J Neurol 5(14):8–14Google Scholar
  22. 22.
    Ashtari F, Shayegannejad V, Saberi A, Rabiei E (2008) Relationship between Helicobacter pylori immunoglobulin g antibody and thrombotic ischemic stroke. Acta Medica Iranica 46(4):303–306Google Scholar
  23. 23.
    Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part I: the role of infection. Part II: noninfectious factors. Ann Neurol;61:288–299. Ann Neurol 61:504–513PubMedGoogle Scholar
  24. 24.
    Szczucinski A, Losy J (2006) Infectious agents in the pathogenesis of multiple sclerosis. Przegl Epidemiol 60(Suppl 1):160–165PubMedGoogle Scholar
  25. 25.
    Dighiero G, Rose NR (1999) Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity. Immunol Today 20:423–428PubMedGoogle Scholar
  26. 26.
    Banks T, Rouse B (1992) Herpesviruses—immune escape artists? Clin Inf Dis 14:933–941Google Scholar
  27. 27.
    Pormohammad A, Azimi T, Falah F, Faghihloo E (2018) Relationship of human herpes virus 6 and multiple sclerosis: a systematic review and meta-analysis. J Cell Physiol 233(4):2850–2862PubMedGoogle Scholar
  28. 28.
    Swanborg RH, Whittum-Hudson JA, Hudson AP (2003) Infectious agents and multiple sclerosis –are Chlamydia pneumoniae and human herpes virus 6 involved? J Neuroimmunol 136(1–2):1–8PubMedGoogle Scholar
  29. 29.
    Fotheringham J, Jacobson S (2005) Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease. Herpes 12;4–9PubMedGoogle Scholar
  30. 30.
    Stratton CW, Wheldon DB (2006) Multiple sclerosis: an infectious syndrome involving Chlamydophila pneumonia. Trends Microbiol 14(11):474–479PubMedGoogle Scholar
  31. 31.
    Cook SD (2004) Does Epstein–Barr virus cause multiple sclerosis? Rev Neurol Dis 1:115–123PubMedGoogle Scholar
  32. 32.
    Christensen T (2006) The role of EBV in MS pathogenesis. Int MS J 13:52–57PubMedGoogle Scholar
  33. 33.
    Ordo˜nez G, Pineda B, Garcia-Navarrete R, Sotelo J (2004) Brief presence of varicellazoster viral DNA in mononuclear cells during relapses of multiple sclerosis. Arch Neurol 61:529–532Google Scholar
  34. 34.
    Tarrats R, Ordo˜nez G, Rios C, Sotelo J (2002) Varicella, ephemeral breastfeeding and eczema as risk factors for multiple sclerosis in Mexicans. Acta Neurol Scand 105:88–94PubMedGoogle Scholar
  35. 35.
    Cirino F, Webley WC, West C, Croteau NL, Andrzejewski C Jr, Stuart ES (2006) Detection of Chlamydia in the peripheral blood cells of normal donors using in vitro culture, immunofluorescence microscopy, and flow cytometry techniques. BMC Infect Dis 6:23PubMedGoogle Scholar
  36. 36.
    Jaruvongvanich V, Sanguankeo A, Jaruvongvanich S, Upala S (2016) Association between Helicobacter pylori infection and multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord 7:92–97PubMedGoogle Scholar
  37. 37.
    Wang ZY, Hansen K, Sidén A, Cruz M (1993) Intrathecal synthesis of anti-Borrelia burgdorferi antibodies in neuroborreliosis: a study with special emphasis on oligoclonal IgM antibody bands. Scand J Immunol 37:369–376PubMedGoogle Scholar
  38. 38.
    Sherbet G (2009) Bacterial infections and the pathogenesis of autoimmune conditions. Br J Med Pract 2:6–13Google Scholar
  39. 39.
    Ercolini AM, Miller SD (2009) The role of infections in autoimmune disease. Clin Exp Immunol 155:1–15PubMedGoogle Scholar
  40. 40.
    Berger T, Reind M (2015) Antibody biomarkers in CNS demyelinating diseases—a long and winding road. Eur J Neurol 22:1162–1168PubMedGoogle Scholar
  41. 41.
    Levin MC, Lee S, Gardner LA, Shin Y, Douglas JN, Cooper Ch (2013) Autoantibodies to non-myelin antigens as contributors to the pathogenesis of multiple sclerosis. J Clin Cell Immunol.  https://doi.org/10.4172/2155-9899.1000148 PubMedGoogle Scholar
  42. 42.
    Fraussen J, Claes N, de Bock L, Somers V (2014) Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev 13:1126–1137PubMedGoogle Scholar
  43. 43.
    Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA et al (2016) STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaborate. BMJ Open 6(11): e012799PubMedGoogle Scholar
  44. 44.
    Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52(6):377–384PubMedGoogle Scholar
  45. 45.
    Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231PubMedGoogle Scholar
  46. 46.
    Wuest SC, Mexhitaj I, Chai NR, Romm E, Scheffel J et al (2014) A complex role of herpes viruses in the disease process of multiple sclerosis. PLoS One 9(8):e105434PubMedGoogle Scholar
  47. 47.
    McKay KA, Kwan V, Duggan T, Tremlett H (2015) Risk factors associated with the onset of relapsing–remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int.  https://doi.org/10.1155/2015/817238 PubMedGoogle Scholar
  48. 48.
    Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H et al (2000) Association between clinical disease activity and Epstein–Barr virus reactivation in MS. Neurology 55(2):178–184PubMedGoogle Scholar
  49. 49.
    Cermelli C, Jacobson S (2000) Viruses and multiple sclerosis. Viral Immunol 13:255–267PubMedGoogle Scholar
  50. 50.
    Villoslada P, Juste C, Tintore M, Llorenç V, Codina G, Pozo-Rosich P et al (2003) The immune response against herpesvirus is more prominent in the early stages of MS. Neurology 60:1944–8PubMedGoogle Scholar
  51. 51.
    Simpson S Jr, Taylor B, Dwyer DE, Taylor J, Blizzard L, Ponsonby AL et al (2012) Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Mult Scler 18(6):799–806PubMedGoogle Scholar
  52. 52.
    Garcia-Montojo M, De Las Heras V, Dominguez-Mozo M, Bartolome M, Garcia-Martinez MA, Arroyo R et al (2011) Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients. Eur J Neurol 18(8):1027–1035PubMedGoogle Scholar
  53. 53.
    Behzad-Behbahani A, Mikaeili MH, Entezam M, Mojiri A, Pour GY, Arasteh MM et al (2011) Human herpesvirus-6 viral load and antibody titer in serum samples of patients with multiple sclerosis. J Microbiol Immunol Infect 44(4):247–251PubMedGoogle Scholar
  54. 54.
    Ahram M, El-Omar A, Baho Y, Lubad MA (2009) Association between human herpesvirus 6 and occurrence of multiple sclerosis among Jordanian patients. Acta Neurol Scand 120(6):430–435PubMedGoogle Scholar
  55. 55.
    Koch WC (2001) Fifth (human parvovirus) and sixth (herpesvirus 6) diseases. Curr Opin Infect Dis 14:343–356PubMedGoogle Scholar
  56. 56.
    Nora-Krukle Z, Chapenko S, Logina I, Millers A, Platkajis A, Murovska M (2011) Human herpesvirus 6 and 7 reactivation and disease activity in multiple sclerosis. Medicina (Kaunas) 47(10):527–531Google Scholar
  57. 57.
    Rodríguez-Violante M, Ordoñez G, Bermudez JR, Sotelo J, Corona T (2009) Association of a history of varicella virus infection with multiple sclerosis. Clin Neurol Neurosurg 111(1):54–56PubMedGoogle Scholar
  58. 58.
    Sotelo J, Ordoñez G, Pineda B, Flores J (2014) The participation of varicella zoster virus in relapses of multiple sclerosis. Clin Neurol Neurosurg 119:44–48PubMedGoogle Scholar
  59. 59.
    Ascherio A, Munger KL (2010) Epstein–Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 5:271–277PubMedGoogle Scholar
  60. 60.
    Warner HB, Carp RI (1981) Multiple sclerosis and Epstein–Barr virus. Lancet 2(8258):1290PubMedGoogle Scholar
  61. 61.
    Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007) Cellular responses to viral infection in humans: lessons from Epstein–Barr virus. Annu Rev Immunol 25:587–617PubMedGoogle Scholar
  62. 62.
    Magliozzi R, Serafini B, Rosicarelli B, Chiappetta G, Veroni C, Reynolds R et al (2013) B-cell enrichment and Epstein–Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol 72:29–41PubMedGoogle Scholar
  63. 63.
    Correale J, Gaitán MI, Ysrraelit MC, Fiol MP (2017) Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain 140(3):527–546PubMedGoogle Scholar
  64. 64.
    Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A et al (2008) Strong EBV-specific CD8 + T-cell response in patients with early multiple sclerosis. Brain 131(Pt 7):1712–1721PubMedGoogle Scholar
  65. 65.
    Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA (2004) Acute infection with Epstein–Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol 78(10):5194–5204PubMedGoogle Scholar
  66. 66.
    van Sechel AC, Bajramovic JJ, van Stipdonk MJ, Persoon-Deen C, Geutskens SB, van Noort JM (1999) EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 162:129–135PubMedGoogle Scholar
  67. 67.
    Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A et al (1995) Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing–remitting multiple sclerosis is associated with disease activity. Ann Neurol 37(1):82–88PubMedGoogle Scholar
  68. 68.
    Giovannoni G, Lai M, Kidd D, Thorpe JW, Miller DH, Thompson AJ et al (1997) Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain 120(Pt 1):1–13PubMedGoogle Scholar
  69. 69.
    Ott M, Seidl C, Westhoff U, Stecker K, Seifried E, Fischer PA et al (1998) Soluble HLA class I and class II antigens in patients with multiple sclerosis. Tissue Antigens 51(3):301–304PubMedGoogle Scholar
  70. 70.
    Fujinami RS, Oldstone MB (1985) Amino acid homology between the encephalolitogenic site of myelin basic protein and virus: mechanisms for autoimmunity. Science 230:1043–1045PubMedGoogle Scholar
  71. 71.
    Wucherpfennig KW, Strominger JL (1995) Molecular mimicry in T cell mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695–705PubMedGoogle Scholar
  72. 72.
    Hemmer B, Fleckenstein BT, Vergelli M, Jung G, McFarland H, Martin R et al (1997) Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J Exp Med 185:1651–1659PubMedGoogle Scholar
  73. 73.
    Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML et al (1995) Expression of costimulatory molecules B7–1 (CD80), B7–2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 182(6):1985–1996PubMedGoogle Scholar
  74. 74.
    Colby BM, Shaw JE, Elion GB, Pagano JS (1980) Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein–Barr virus DNA replication. J Virol 34(2):560–568PubMedGoogle Scholar
  75. 75.
    Weiner HL (2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous. Disease? Ann Neurol 65:239–248PubMedGoogle Scholar
  76. 76.
    Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J et al (2009) Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 73(1):32–38PubMedGoogle Scholar
  77. 77.
    Ramroodi N, Niazi AA, Sanadgol N, Ganjali Z, Sarabandi V (2013) Evaluation of reactive Epstein–Barr virus (EBV) in Iranian patient with different subtypes of multiple sclerosis (MS). Braz J Infect Dis 17(2):156–163PubMedGoogle Scholar
  78. 78.
    Munger KL, Levin LI, O’Reilly EJ, Falk KI, Ascherio A (2011) Anti-Epstein–Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 17(10):1185–1193PubMedGoogle Scholar
  79. 79.
    Yea C, Tellier R, Chong P, Westmacott G, Marrie RA, Bar-Or A et al (2013) Epstein–barr virus in oral shedding of children with multiple sclerosis. Neurology 81(16):1392–1399PubMedGoogle Scholar
  80. 80.
    Ingram G, Bugert JJ, Loveless S, Robertson NP (2010) Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. Eur J Neurol 17(11):1386–1389PubMedGoogle Scholar
  81. 81.
    Boelen E, Steinbusch HW, van der Ven AJ, Grauls G, Bruggeman CA, Stassen FR (2007) Chlamydia pneumoniae infection of brain cells: an in vitro study. Neurobiol Aging 28(4):524–532PubMedGoogle Scholar
  82. 82.
    Aghaei M, Ashtari F, Bahar M, Falahian MR (2011) Chlamydia pneumoniae seropositivity in Iranian patients with multiple sclerosis: a pilot study. Neurol Neurochir Pol 45(2):128–131PubMedGoogle Scholar
  83. 83.
    Rindfleisch E (1863) Histologisches detail zu der grauen degeneration von gehirn und ruckenmark. Arch Pathol Anat Physiol 26(5–6):474–483Google Scholar
  84. 84.
    Mattson MP (2004) Infectious agents and age-related neurodegenerative disorders. Ageing Res Rev 3:105–120PubMedGoogle Scholar
  85. 85.
    Contini C, Cultrera R, Seraceni S, Castellazzi M, Granieri E, Fainardi E (2004) Cerebrospinal fluid molecular demonstration of Chlamydia pneumonia DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing/remitting multiple sclerosis. Mult Scler 10(4):360–369PubMedGoogle Scholar
  86. 86.
    Munger KL, Peeling RW, Hernán MA, Chasan-Taber L, Olek MJ, Hankinson SE et al (2003) Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology 14(2):141–7PubMedGoogle Scholar
  87. 87.
    Munger KL, DeLorenze GN, Levin LI, Rubertone MV, Vogelman JH, Peck CA et al (2004) A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts. Neurology 62(10):1799–1803PubMedGoogle Scholar
  88. 88.
    Krametter D, Niederwieser G, Berghold A, Birnbaum G, Strasser-Fuchs S, Hartung HP et al (2001) Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker. Mult Scler 7(1):13–18PubMedGoogle Scholar
  89. 89.
    Fainardi E, Castellazzi M, Casetta I, Cultrera R, Vaghi L, Granieri E et al (2004) Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated with a subset of multiple sclerosis patients with progressive forms. J Neurol Sci 217(2):181–188PubMedGoogle Scholar
  90. 90.
    Agostini HT, Ryschkewitsch CF, Baumhefner RW, Tourtellotte WW, Singer EJ, Komoly S et al (2000) Influence of JC virus coding region genotype on risk of multiple sclerosis and progressive multifocal leukoencephalopathy. J Neurovirol 6(2):101–108Google Scholar
  91. 91.
    Rasmussena HB, Kellyb MA, Francisc DA, Clausena J (2000) Association between the endogenous retrovirus HRES-1 and multiple sclerosis in the United Kingdom—evidence of genetically different disease subsets? Dis Markers 16(3–4):101–104Google Scholar
  92. 92.
    Chan PK, Tam WH, Yeo W, Cheung JL, Zhong S, Cheng AF (2001) High carriage rate of TT virus in the cervices of pregnant women. Clin Infect Dis 32(9):1376–1377PubMedGoogle Scholar
  93. 93.
    Rocchi J, Ricci V, Albani M, Lanini L, Andreoli E, Macera L et al (2009) Torque teno virus DNA drives proinflammatory cytokines production and secretion by immune cells via toll-like receptor 9. Virology 394(2):235–42PubMedGoogle Scholar
  94. 94.
    Mancuso R, Saresella M, Hernis A, Agostini S, Piancone F, Caputo D et al (2013) Torque teno virus (TTV) in multiple sclerosis patients with different patterns of disease. J Med Virol 85(12):2176–2183PubMedGoogle Scholar

Copyright information

© Belgian Neurological Society 2018

Authors and Affiliations

  • Alia Saberi
    • 1
  • Shahin Akhondzadeh
    • 2
  • Samaneh Kazemi
    • 3
  1. 1.Neuroscience Research Center, Department of Neurology, Poursina Hospital, School of MedicineGuilan University of Medical SciencesRashtIran
  2. 2.Psychiatric Research Center, Roozbeh HospitalTehran University of Medical SciencesTehranIran
  3. 3.Deputy of Research and TechnologyGuilan University of Medical SciencesRashtIran

Personalised recommendations